u/Busy_Pair_5883

https://x.com/resilient333/status/2070858904024596854

Chris Rogers, 42, and his brother Dave Rogers, 37, both died suddenly within days of each other. Both appeared to be in good health just months before their untimely deaths.

June 15, 2026 *Dave Rogers, 37, tragically died suddenly and unexpectedly-"an Aneurysm out of nowhere.

June 19, 2026 *Tragically, Chris Rogers, 42, died suddenly and unexpectedly from progressive fluid buildup and organ failure originating from an underlying, severely damaged liver.

https://x.com/resilient333/status/2069407766951629009

*May 21, 2026 *Tragically, Minnie died suddenly and unexpectedly at 38.

*Matthew "Matty" Paul Frederick Parker *"loving father and family man who embraced his unique personality and loved the outdoors" *June 8, 2026 *Tragically, Matthew died suddenly and unexpectedly at 37.

*Gareth "Gary"Wayne Willmott *"A beloved community member known for his love of rugby league, particularly the Cherbourg Hornets" *June 14, 2026 *Tragically, Gareth died suddenly and unexpectedly at 38.

https://www.reddit.com/r/GriefSupport/comments/1ubudoa/last_year_i_made_a_dead_dad_club_members_check_in/

read comments, count how many dads have died

this post is from https://www.reddit.com/r/GriefSupport/comments/1u06lkm/my_entire_family_died/

"I am only 41 years old and nearly my entire family has passed away and I don’t know how I’m going to face the rest of my life."

https://x.com/TrueOnX/status/2062215645077631440

Look at this. Someone just pulled these long, rubbery WHITE FIBERS out of a perfectly cooked brisket. They stretch like taffy and don’t break.

https://x.com/NicHulscher/status/2060366485730525399

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%)